Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.79 |
| ▸ | MPC2 | O95563 | 2/20 | 0.79 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitoglitazone SCHEMBL622605 | 0.88 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| Mitoglitazone SCHEMBL18541503 | 0.88 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| Mitoglitazone SCHEMBL18538169 | 0.88 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| Mitoglitazone SCHEMBL18541482 | 0.88 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| Mitoglitazone SCHEMBL2221702 | 0.88 | PPARG (0.98) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| SCHEMBL10085212 | 0.88 | PPARG (0.79) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| SCHEMBL14408626 | 0.87 | PPARG (0.78) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| SCHEMBL11929116 | 0.86 | PPARG (0.76) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| Mitoglitazone SCHEMBL2221427 | 0.85 | PPARG (0.92) | PPARGMPC2CYP2C8CYP2C9CYP3A4 | |
| SCHEMBL10106198 | 0.84 | PPARG (0.74) | PPARGMPC2CYP2C8CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389556-B2 | Thiazolidinedione analogues | Metabolic Soultions Development Company, LLC (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120015982-A1 | Thiazolidinedione analogues | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2007109024-A2 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF METABOLIC INFLAMMATION MEDIATED DISEASE | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015982-A1 | Thiazolidinedione analogues | PPARD, GLP1R, PPARG | PPARG 3/4885MPC2 142/4885CYP2C8 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.